In a previous study, we systematically characterized the in vitro effects of ASP3026, an orally available second-generation ALK inhibitor, in NPM-ALK+ T cell lymphoma cell lines [26]. This evidence concerns the gene ALK and T-cell non-Hodgkin lymphoma.